Human Induced Pluripotent Stem Cell and Nanotechnology-Based Therapeutics

Human induced pluripotent stem cells (hiPSCs) can be genetically reprogrammed to an embryonic stem cell-like state and can provide promising medical applications, such as diagnosis, prognosis, drug screening for therapeutical development, and monitoring disease progression. Despite myriad advances, traditional viral-based reprogramming for generating hiPSCs has safety risks that hinder further practical applications of hiPSCs. In the past decade, nonviral-based reprogramming has been used as an alternative to produce hiPSCs and enhance their differentiation. In addition, the efficiency of nonviral-based reprogramming is generally poor, compared to that of viral-based reprogramming. Recent studies in nanoscale-structured particles have made progress in addressing many applications of hiPSCs for clinical practice. The combination of hiPSCs and nanotechnology will actually act as the therapeutic platform for personalized medicine and can be the remedies against various diseases in the future. In this article, we review recent advances in cellular reprogramming and hiPSC-related research, such as cell source, delivery system, and direct reprogramming, as well as some of its potential clinical applications, including mitochondrial and retinal disease. We also briefly summarize the current incorporation of nanotechnology in patient-specific hiPSCs for future treatments.

[1]  A. Giordano,et al.  A Commentary on iPS Cells: Potential Applications in Autologous Transplantation, Study of Illnesses and Drug Screening , 2014, Journal of cellular physiology.

[2]  Kwangmeyung Kim,et al.  Dextran sulfate-coated superparamagnetic iron oxide nanoparticles as a contrast agent for atherosclerosis imaging. , 2014, Carbohydrate polymers.

[3]  A. Herrmann,et al.  Drug delivery systems based on nucleic acid nanostructures. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[4]  Jiangnan Yu,et al.  Non‐Viral Co‐Delivery of the Four Yamanaka Factors for Generation of Human Induced Pluripotent Stem Cells via Calcium Phosphate Nanocomposite Particles , 2013 .

[5]  S. Chiou,et al.  Nonviral cell labeling and differentiation agent for induced pluripotent stem cells based on mesoporous silica nanoparticles. , 2013, ACS nano.

[6]  Eun Jin Seo,et al.  Efficient Production of Retroviruses Using PLGA/bPEI-DNA Nanoparticles and Application for Reprogramming Somatic Cells , 2013, PloS one.

[7]  Dong Ryul Lee,et al.  Therapeutic Potential of Human Induced Pluripotent Stem Cells in Experimental Stroke , 2013, Cell transplantation.

[8]  A. Wan,et al.  Delivery of reprogramming factors into fibroblasts for generation of non-genetic induced pluripotent stem cells using a cationic bolaamphiphile as a non-viral vector. , 2013, Biomaterials.

[9]  Y. Yoon,et al.  Induction of pluripotency in bone marrow mononuclear cells via polyketal nanoparticle-mediated delivery of mature microRNAs. , 2013, Biomaterials.

[10]  T. Buchholz,et al.  Derivation and characterization of sleeping beauty transposon-mediated porcine induced pluripotent stem cells. , 2013, Stem cells and development.

[11]  Jun Liu,et al.  Curcumin Ameliorates the Neurodegenerative Pathology in A53T α-synuclein Cell Model of Parkinson’s Disease Through the Downregulation of mTOR/p70S6K Signaling and the Recovery of Macroautophagy , 2013, Journal of Neuroimmune Pharmacology.

[12]  Eun Young Kim,et al.  Efficient Generation of Virus-Free iPS Cells Using Liposomal Magnetofection , 2012, PloS one.

[13]  Leaf Huang,et al.  Recent advances in nonviral vectors for gene delivery. , 2012, Accounts of chemical research.

[14]  Peter Wernet,et al.  Small molecules enable highly efficient neuronal conversion of human fibroblasts , 2012, Nature Methods.

[15]  E. Finch,et al.  MicroRNA-Mediated In Vitro and In Vivo Direct Reprogramming of Cardiac Fibroblasts to Cardiomyocytes , 2012, Circulation research.

[16]  Silvia Licoccia,et al.  Cerium oxide nanoparticles protect cardiac progenitor cells from oxidative stress. , 2012, ACS nano.

[17]  Jeffrey T. Leek,et al.  Personalized medicine: Keep a way open for tailored treatments , 2012, Nature.

[18]  G. Daley,et al.  The promise of induced pluripotent stem cells in research and therapy , 2012, Nature.

[19]  S. Cole,et al.  Sequences Human Induced Pluripotent Stem Cells Free of Vector and Transgene , 2012 .

[20]  Seung‐Woo Cho,et al.  Nonviral delivery of genetic medicine for therapeutic angiogenesis. , 2012, Advanced drug delivery reviews.

[21]  B. Strulovici,et al.  Induced pluripotent stem cells — opportunities for disease modelling and drug discovery , 2011, Nature Reviews Drug Discovery.

[22]  J. Nolta,et al.  Effects on Proliferation and Differentiation of Multipotent Bone Marrow Stromal Cells Engineered to Express Growth Factors for Combined Cell and Gene Therapy , 2011, Stem cells.

[23]  Maria Teresa Dell'Anno,et al.  Direct generation of functional dopaminergic neurons from mouse and human fibroblasts , 2011, Nature.

[24]  S. Yamanaka,et al.  The Use of Induced Pluripotent Stem Cells in Drug Development , 2011, Clinical pharmacology and therapeutics.

[25]  R. Stewart,et al.  Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells. , 2011, Blood.

[26]  Stéphanie Boué,et al.  Methods for making induced pluripotent stem cells: reprogramming à la carte , 2011, Nature Reviews Genetics.

[27]  Gang Wang,et al.  Conversion of mouse fibroblasts into cardiomyocytes using a direct reprogramming strategy , 2011, Nature Cell Biology.

[28]  Bernadett Papp,et al.  Reprogramming to pluripotency: stepwise resetting of the epigenetic landscape , 2011, Cell Research.

[29]  N. Montserrat,et al.  Simple Generation of Human Induced Pluripotent Stem Cells Using Poly-β-amino Esters As the Non-viral Gene Delivery System* , 2011, The Journal of Biological Chemistry.

[30]  P. Mali,et al.  Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures , 2011, Cell Research.

[31]  Fred H. Gage,et al.  A Model for Neural Development and Treatment of Rett Syndrome Using Human Induced Pluripotent Stem Cells , 2010, Cell.

[32]  Alexander Meissner,et al.  Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. , 2010, Cell stem cell.

[33]  Krishanu Saha,et al.  Pluripotency and Cellular Reprogramming: Facts, Hypotheses, Unresolved Issues , 2010, Cell.

[34]  Lei Yang,et al.  Patient-specific induced pluripotent stem cell derived models of LEOPARD syndrome , 2010, Nature.

[35]  Hsin-Yang Li,et al.  Functional improvement of focal cerebral ischemia injury by subdural transplantation of induced pluripotent stem cells with fibrin glue. , 2010, Stem cells and development.

[36]  Deepak M. Gupta,et al.  A nonviral minicircle vector for deriving human iPS cells , 2010, Nature Methods.

[37]  C. Dang,et al.  Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. , 2009, Blood.

[38]  Krishanu Saha,et al.  Technical challenges in using human induced pluripotent stem cells to model disease. , 2009, Cell stem cell.

[39]  Wen-Yueh Ho,et al.  The characteristics and transfection efficiency of cationic poly (ester-co-urethane) - short chain PEI conjugates self-assembled with DNA. , 2009, Biomaterials.

[40]  Wenbo Zhou,et al.  Adenoviral Gene Delivery Can Reprogram Human Fibroblasts to Induced Pluripotent Stem Cells , 2009, Stem cells.

[41]  A. Viale,et al.  Modeling Pathogenesis and Treatment of Familial Dysautonomia using Patient Specific iPSCs , 2009, Nature.

[42]  Kristopher L. Nazor,et al.  Adult mice generated from induced pluripotent stem cells , 2009, Nature.

[43]  Qi Zhou,et al.  iPS cells produce viable mice through tetraploid complementation , 2009, Nature.

[44]  A. Consiglio,et al.  Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells , 2009, Nature.

[45]  G. Daley,et al.  Generation of induced pluripotent stem cells from human blood. , 2009, Blood.

[46]  R. Stewart,et al.  Human Induced Pluripotent Stem Cells Free of Vector and Transgene Sequences , 2009, Science.

[47]  Wei Wang,et al.  piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells , 2009, Nature.

[48]  Huck-Hui Ng,et al.  Molecules that promote or enhance reprogramming of somatic cells to induced pluripotent stem cells. , 2009, Cell stem cell.

[49]  Rudolf Jaenisch,et al.  Parkinson's Disease Patient-Derived Induced Pluripotent Stem Cells Free of Viral Reprogramming Factors , 2009, Cell.

[50]  James A. Thomson,et al.  Induced pluripotent stem cells from a spinal muscular atrophy patient , 2009, Nature.

[51]  M. Shau,et al.  The synthesis of cationic polyurethanes to study the effect of amines and structures on their DNA transfection potential. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[52]  Shinya Yamanaka,et al.  Generation of Mouse Induced Pluripotent Stem Cells Without Viral Vectors , 2008, Science.

[53]  A. Consiglio,et al.  Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes , 2008, Nature Biotechnology.

[54]  George Q. Daley,et al.  Disease-Specific Induced Pluripotent Stem Cells , 2008, Cell.

[55]  Hynek Wichterle,et al.  Induced Pluripotent Stem Cells Generated from Patients with ALS Can Be Differentiated into Motor Neurons , 2008, Science.

[56]  T. Mikkelsen,et al.  Dissecting direct reprogramming through integrative genomic analysis , 2008, Nature.

[57]  Eric S. Lander,et al.  Dissecting direct reprogramming through integrative genomic analysis , 2008, Nature.

[58]  L. Pelus.  Peripheral blood stem cell mobilization: new regimens, new cells, where do we stand , 2008, Current opinion in hematology.

[59]  R. Jaenisch,et al.  Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease , 2008, Proceedings of the National Academy of Sciences.

[60]  B. Thiers.  Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2008 .

[61]  Shulan Tian,et al.  Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells , 2007, Science.

[62]  S. Yamanaka,et al.  Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.

[63]  M. Shau,et al.  Effect of molecular weight on the transfection efficiency of novel polyurethane as a biodegradable gene vector. , 2006, Journal of biomedical materials research. Part A.

[64]  K. Foitzik,et al.  Biology of the hair follicle: the basics. , 2006, Seminars in cutaneous medicine and surgery.

[65]  M. Shau,et al.  Structural characterization and buffering capacity in relation to the transfection efficiency of biodegradable polyurethane. , 2005, Bioconjugate chemistry.

[66]  Michael S Sacks,et al.  Preparation and characterization of highly porous, biodegradable polyurethane scaffolds for soft tissue applications. , 2005, Biomaterials.

[67]  V. Botchkarev.  Molecular mechanisms of chemotherapy-induced hair loss. , 2003, The journal of investigative dermatology. Symposium proceedings.

[68]  Mark A. Kay,et al.  Progress and problems with the use of viral vectors for gene therapy , 2003, Nature Reviews Genetics.

[69]  A. McGregor.  Transposon and transposome mutagenesis of plasmids, cosmids, and BACs. , 2003, Methods in molecular biology.

[70]  W. Thomson,et al.  The Arthritis and Rheumatism Council's National Repository of Family Material: pedigrees from the first 100 rheumatoid arthritis families containing affected sibling pairs. , 1994, British journal of rheumatology.

[71]  P. Gerber,et al.  Selective transformation of B lymphocytes by E.B. virus. , 1973, Lancet.